Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management led a $177m Series A round in Antares Therapeutics.

Investment firms Omega Funds, Atlas Venture, Lightspeed Venture Partners, BVF Partners, and Cormorant Asset Management led a $177m Series A round in Antares Therapeutics, a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, with participation from Vinyanshu Ventures, Abingworth, Invus, Tenmile, Vida Ventures, and Willett Advisors. “We took our name from Antares, the brightest star in the Scorpius constellation, and known as ‘the heart of the Scorpion.’ We are building from a strong foundation with a team of experts who are experienced in making new medicines, as well as proprietary drug discovery capabilities and a robust preclinical pipeline fueled by discoveries in drugging previously inaccessible targets. We are committed to leveraging our expertise to address well-validated, first-in-class targets across oncology and other serious diseases, and to continuing to execute a fast-to-clinic strategy to bring medicines to patients in need,” Adam Friedman, Antares CEO.